- We will send in 10–14 business days.
/images/books/10027855/9781461444985.jpg)
- Author: Pete Humphries
- Publisher: Springer
- Year: 2012
- Pages: 46
- ISBN-10: 1461444985
- ISBN-13: 9781461444985
- Format: 15 x 22.6 x 0.5 cm, minkšti viršeliai
- Language: English
- SAVE -10% with code: EXTRA
Reviews
Description
The hereditary retinopathy, retinitis pigmentosa (RP), which affects 1 in 3,500 people worldwide, is the most common cause of registered visual handicap among those of the working age in developed countries. RP is a highly variable disorder where patients may develop symptomatic visual loss in early childhood, while others may remain asymptomatic until mid-adulthood. Most cases of RP segregate in autosomal dominant, recessive or X-linked recessive modes, with approximately 41 genes being implicated in disease pathology to date (RetNet). The extensive genetic heterogeneity associated with autosomal dominant RP (adRP) is an undisputed hindrance to the development of genetically based therapeutics.
EXTRA 10 % discount with code: EXTRA
The promotion ends in 23d.07:26:32
The discount code is valid when purchasing from 10 €. Discounts do not stack.
- Author: Pete Humphries
- Publisher: Springer
- Year: 2012
- Pages: 46
- ISBN-10: 1461444985
- ISBN-13: 9781461444985
- Format: 15 x 22.6 x 0.5 cm, minkšti viršeliai
- Language: English English
The hereditary retinopathy, retinitis pigmentosa (RP), which affects 1 in 3,500 people worldwide, is the most common cause of registered visual handicap among those of the working age in developed countries. RP is a highly variable disorder where patients may develop symptomatic visual loss in early childhood, while others may remain asymptomatic until mid-adulthood. Most cases of RP segregate in autosomal dominant, recessive or X-linked recessive modes, with approximately 41 genes being implicated in disease pathology to date (RetNet). The extensive genetic heterogeneity associated with autosomal dominant RP (adRP) is an undisputed hindrance to the development of genetically based therapeutics.
Reviews